1
|
Quaife NM, Chothani S, Schulz JF, Lindberg EL, Vanezis K, Adami E, O'Fee K, Greiner J, Litviňuková M, van Heesch S, Whiffin N, Hubner N, Schafer S, Rackham O, Cook SA, Barton PJR. LINC01013 Is a Determinant of Fibroblast Activation and Encodes a Novel Fibroblast-Activating Micropeptide. J Cardiovasc Transl Res 2023; 16:77-85. [PMID: 35759180 PMCID: PMC9944705 DOI: 10.1007/s12265-022-10288-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/15/2021] [Accepted: 06/09/2022] [Indexed: 10/17/2022]
Abstract
Myocardial fibrosis confers an almost threefold mortality risk in heart disease. There are no prognostic therapies and novel therapeutic targets are needed. Many thousands of unannotated small open reading frames (smORFs) have been identified across the genome with potential to produce micropeptides (< 100 amino acids). We sought to investigate the role of smORFs in myocardial fibroblast activation.Analysis of human cardiac atrial fibroblasts (HCFs) stimulated with profibrotic TGFβ1 using RNA sequencing (RNA-Seq) and ribosome profiling (Ribo-Seq) identified long intergenic non-coding RNA LINC01013 as TGFβ1 responsive and containing an actively translated smORF. Knockdown of LINC01013 using siRNA reduced expression of profibrotic markers at baseline and blunted their response to TGFβ1. In contrast, overexpression of a codon-optimised smORF invoked a profibrotic response comparable to that seen with TGFβ1 treatment, whilst FLAG-tagged peptide associated with the mitochondria.Together, these data support a novel LINC01013 smORF micropeptide-mediated mechanism of fibroblast activation. TGFβ1 stimulation of atrial fibroblasts induces expression of LINC01013, whose knockdown reduces fibroblast activation. Overexpression of a smORF contained within LINC01013 localises to mitochondria and activates fibroblasts.
Collapse
Affiliation(s)
- N M Quaife
- National Heart and Lung Institute, Imperial College London, London, UK
- MRC London Institute of Medical Sciences, London, UK
| | - S Chothani
- Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore, Singapore, 169857, Singapore
| | - J F Schulz
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
- DZHK (German Center for Cardiovascular Research), partner site Berlin, Berlin, Germany
| | - E L Lindberg
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - K Vanezis
- National Heart and Lung Institute, Imperial College London, London, UK
- MRC London Institute of Medical Sciences, London, UK
| | - E Adami
- Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore, Singapore, 169857, Singapore
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - K O'Fee
- MRC London Institute of Medical Sciences, London, UK
| | - J Greiner
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - M Litviňuková
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - S van Heesch
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
| | - N Whiffin
- National Heart and Lung Institute, Imperial College London, London, UK
- Cardiovascular Research Centre, Royal Brompton and Harefield Hospitals, Guy's and St Thomas NHS Foundation Trust, London, UK
- Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK
| | - N Hubner
- Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
- DZHK (German Center for Cardiovascular Research), partner site Berlin, Berlin, Germany
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - S Schafer
- Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore, Singapore, 169857, Singapore
| | - O Rackham
- Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore, Singapore, 169857, Singapore
| | - S A Cook
- MRC London Institute of Medical Sciences, London, UK
- Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore, Singapore, 169857, Singapore
- National Heart Centre Singapore, Singapore, Singapore
| | - P J R Barton
- National Heart and Lung Institute, Imperial College London, London, UK.
- MRC London Institute of Medical Sciences, London, UK.
- Cardiovascular Research Centre, Royal Brompton and Harefield Hospitals, Guy's and St Thomas NHS Foundation Trust, London, UK.
| |
Collapse
|
2
|
Quaife NM, Chothani S, Schulz JF, Lindberg EL, Vanezis K, Adami E, O’Fee K, Greiner J, Litviňuková M, van Heesch S, Whiffin N, Hubner N, Schafer S, Rackham O, Cook SA, Barton PJR. Correction to: LINC01013 Is a Determinant of Fibroblast Activation and Encodes a Novel Fibroblast-Activating Micropeptide. J Cardiovasc Transl Res 2023; 16:86. [PMID: 35834119 PMCID: PMC9944001 DOI: 10.1007/s12265-022-10291-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Affiliation(s)
- N. M. Quaife
- grid.7445.20000 0001 2113 8111National Heart and Lung Institute, Imperial College London, London, UK ,grid.14105.310000000122478951MRC London Institute of Medical Sciences, London, UK
| | - S. Chothani
- grid.428397.30000 0004 0385 0924Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore, Singapore, 169857 Singapore
| | - J. F. Schulz
- grid.419491.00000 0001 1014 0849Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany ,grid.452396.f0000 0004 5937 5237DZHK (German Center for Cardiovascular Research), partner site Berlin, Berlin, Germany
| | - E. L. Lindberg
- grid.419491.00000 0001 1014 0849Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - K. Vanezis
- grid.7445.20000 0001 2113 8111National Heart and Lung Institute, Imperial College London, London, UK ,grid.14105.310000000122478951MRC London Institute of Medical Sciences, London, UK
| | - E. Adami
- grid.428397.30000 0004 0385 0924Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore, Singapore, 169857 Singapore ,grid.419491.00000 0001 1014 0849Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - K. O’Fee
- grid.14105.310000000122478951MRC London Institute of Medical Sciences, London, UK
| | - J. Greiner
- grid.419491.00000 0001 1014 0849Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - M. Litviňuková
- grid.419491.00000 0001 1014 0849Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
| | - S. van Heesch
- grid.487647.ePrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
| | - N. Whiffin
- grid.7445.20000 0001 2113 8111National Heart and Lung Institute, Imperial College London, London, UK ,grid.420545.20000 0004 0489 3985Cardiovascular Research Centre, Royal Brompton and Harefield Hospitals, Guy’s and St Thomas NHS Foundation Trust, London, UK ,grid.4991.50000 0004 1936 8948Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK
| | - N. Hubner
- grid.419491.00000 0001 1014 0849Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany ,grid.452396.f0000 0004 5937 5237DZHK (German Center for Cardiovascular Research), partner site Berlin, Berlin, Germany ,grid.484013.a0000 0004 6879 971XBerlin Institute of Health at Charité – Universitätsmedizin Berlin, Berlin, Germany
| | - S. Schafer
- grid.428397.30000 0004 0385 0924Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore, Singapore, 169857 Singapore
| | - O. Rackham
- grid.428397.30000 0004 0385 0924Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore, Singapore, 169857 Singapore
| | - S. A. Cook
- grid.14105.310000000122478951MRC London Institute of Medical Sciences, London, UK ,grid.428397.30000 0004 0385 0924Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore, Singapore, 169857 Singapore ,grid.419385.20000 0004 0620 9905National Heart Centre Singapore, Singapore, Singapore
| | - P. J. R. Barton
- grid.7445.20000 0001 2113 8111National Heart and Lung Institute, Imperial College London, London, UK ,grid.14105.310000000122478951MRC London Institute of Medical Sciences, London, UK ,grid.420545.20000 0004 0489 3985Cardiovascular Research Centre, Royal Brompton and Harefield Hospitals, Guy’s and St Thomas NHS Foundation Trust, London, UK
| |
Collapse
|
3
|
Sylvia SM, Maguire KJ, Molho DA, Levens BJ, Stone MEJ, Hanstein R, Schulz JF, Fornari ED. Emergency room closed reduction versus in situ splinting in the treatment of paediatric supracondylar humerus fractures. J Child Orthop 2019; 13:334-339. [PMID: 31312275 PMCID: PMC6598037 DOI: 10.1302/1863-2548.13.190018] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
PURPOSE Displaced supracondylar humerus fractures are treated with open or closed reduction and percutaneous pinning. In 2012, our management of patients with a displaced fracture changed from closed reduction in the emergency department (ED) to in situ splinting prior to closed reduction and pinning in the operating room (OR). The purpose of this study was to investigate if outcomes or complications differ between these two management methods. METHODS Patients less than ten years old with a Gartland type II or III supracondylar humerus fracture between 2008 and 2016 were included. Cases of polytrauma were excluded. Radiographic outcomes were assessed at follow-up. The Fisher's exact test was used for categorical variables and the Wilcoxon rank sums tests for continuous variables. RESULTS In all, 157 patients were included, 89 with reduction in the ED and 68 without. There was no significant difference between the groups related to demographic factors or fracture characteristics. Patients managed without reduction in the ED had a lower average delay from ED to OR compared with those treated with reduction (16 hours versus 22 hours, p < 0.005) and a shorter hospital length of stay (34 hours versus 40 hours, p < 0.005). CONCLUSION No difference in complications or outcomes was found between patients with Type II or III supracondylar fractures treated initially with or without closed reduction in the ED. Patients treated without ED reduction were taken to the OR sooner and remained in the hospital for a shorter period of time. Splinting in situ reduces anaesthesia exposure without increasing postoperative complications or suboptimal outcomes. LEVEL OF EVIDENCE Level III, retrospective comparative study.
Collapse
Affiliation(s)
- S. M. Sylvia
- Albert Einstein College of Medicine, Bronx, New York, USA
| | - K. J. Maguire
- Department of Orthopaedic Surgery, Montefiore Medical Center, Bronx, New York, USA
| | - D. A. Molho
- Albert Einstein College of Medicine, Bronx, New York, USA
| | - B. J. Levens
- Department of Orthopaedic Surgery, Montefiore Medical Center, Bronx, New York, USA
| | | | - R. Hanstein
- Division of Pediatric Orthopaedics, Children’s Hospital at Montefiore Medical Center, Bronx, New York, USA
| | - J. F. Schulz
- Division of Pediatric Orthopaedics, Children’s Hospital at Montefiore Medical Center, Bronx, New York, USA
| | - E. D. Fornari
- Division of Pediatric Orthopaedics, Children’s Hospital at Montefiore Medical Center, Bronx, New York, USA,Correspondence should be sent to Eric D. Fornari, MD, 3400 Bainbridge Avenue, Bronx, New York 10467-2404, USA. E-mail:
| |
Collapse
|
4
|
Berko NS, Mehta AK, Levin TL, Schulz JF. Effect of knee position on the ultrasound elastography appearance of the patellar tendon. Clin Radiol 2015; 70:1083-6. [PMID: 26264499 DOI: 10.1016/j.crad.2015.06.100] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2015] [Revised: 06/18/2015] [Accepted: 06/30/2015] [Indexed: 10/23/2022]
Affiliation(s)
- N S Berko
- Department of Radiology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USA.
| | - A K Mehta
- Department of Radiology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USA
| | - T L Levin
- Department of Radiology, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USA
| | - J F Schulz
- Department of Orthopaedic Surgery, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USA
| |
Collapse
|